Insulin injection is mostly used in patients with type 1 DM (T1DM) (JC, 2012), whereas oral medication is generally prescribed to patients with T2DM, which is usually initiated with metformin as the first-line medicine along with combination therapy including other hypoglycemic agents, such as pioglitazone, sulfonylureas, meglitinides, and α-glucosidase inhibitors (Nathan, 2015). The gene discussed is INS; the disease is type 2 diabetes mellitus.